6 reports

  • AUG 29, 2017: ONCBIOMUNE TO PRESENT ABSTRACT ON CLINICAL TRIAL OF NOVEL PROSTATE CANCER VACCINE AT AMERICAN ASSOCIATION OF CANCER RESEARCH SPECIAL CONFERENCE
  • SEP 14, 2017: ONCBIOMUNE MEETS PRIMARY OBJECTIVE IN TRIAL OF PROSCAVAX IMMUNOTHERAPY VACCINE FOR PROSTATE CANCER

Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Pipeline Review, H1 2018 Summary Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) pipeline Target constitutes close to 15 molecules. Out of which...

  • Blood Supply
  • Cancer
  • Prostate Cancer
  • Therapy
  • OncBioMune Pharmaceuticals, Inc.
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H2 2017
  • PIPELINE BY ONCBIOMUNE PHARMACEUTICALS INC, H2 2017

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Pipeline Review, H2 2017 Summary Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) pipeline Target constitutes...

  • Cancer
  • Monoclonal Antibody
  • Prostate Cancer
  • Therapy
  • OncBioMune Pharmaceuticals, Inc.
  • PROSTATE CANCER PATIENTS.
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2018

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Pipeline Review, H1 2018 Summary According to the recently published report ’Prostate Specific Antigen - Pipeline Review, H1 2018’; Prostate Specific Antigen (Gamma Seminoprotein...

  • Cancer
  • Prostate Cancer
  • United States
  • Product Initiative
  • OncBioMune Pharmaceuticals, Inc.
  • JUL 20, 2016: PRE-CLINICAL RESEARCH SUPPORTS ADDITIONAL STUDIES OF ONCBIOMUNE TECHNOLOGY FOR BREAST CANCER VACCINE
  • JUL 13, 2016: ONCBIOMUNE SUBMITS PROTOCOL TO INITIATE PHASE 2/3 TRIAL OF PROSCAVAX FOR PROSTATE CANCER

Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Pipeline Review, H2 2016’, provides in depth analysis on Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) targeted pipeline therapeutics....

  • Cancer
  • Cytokine
  • Prostate Cancer
  • Vaccine
  • OncBioMune Pharmaceuticals, Inc.
  • Melanoma
  • PIPELINE BY ONCBIOMUNE PHARMACEUTICALS INC, H2 2017

Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Pipeline Review, H2 2017 Summary According to the recently published report ’Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha - Pipeline Review, H2 2017’; Granulocyte Macrophage Colony Stimulating...

  • Blood Supply
  • Cancer
  • Prostate Cancer
  • Therapy
  • OncBioMune Pharmaceuticals, Inc.
  • ONCBIOMUNE PHARMA AND VITEL LABS FORMS JOINT VENTURE
  • MAR 19, 2018: ONCBIOMUNE NAMES ROBERT NEAL HOLCOMB TO BOARD OF DIRECTORS

While known to be inherited and considered one of the most common genetic disorders worldwide, no one is certain as to how many people are afflicted with AAT deficiency.

  • Cancer
  • Mexico
  • United States
  • Company
  • OncBioMune Pharmaceuticals, Inc.